NASDAQ$OVID
Ovid Therapeutics Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Ovid Therapeutics reported its business updates and financial results for Q1 2024.
Ovid Therapeutics reported a revenue of $148,000 and a net loss of $11.7 million for the first quarter ended March 31, 2024. The company's cash, cash equivalents, and marketable securities totaled $90.3 million as of March 31, 2024, which is expected to support operations into H1 2026. Takeda has completed two Phase 3 trials studying soticlestat.
- Takeda completed two Phase 3 trials for soticlestat, with topline data expected in Takeda's H1 2024 fiscal year.
- Phase 1 trial for OV888 (GV101) is complete, with topline safety data expected in H1 2024.
- Ovid expects to initiate a Phase 2 clinical program for OV888 (GV101) in cerebral cavernous malformations in H2 2024.
- Cash, cash equivalents, and marketable securities were $90.3 million as of March 31, 2024, supporting operations into H1 2026.
Headline financials
Revenue & EPS history
Ovid Therapeutics · Revenue · Quarterly
$148K
Revenue by segment
Ovid Therapeutics · $5.7M total across 1 segment · Q4 2020
- License and other revenue$5.7M—100.0%
Forward guidance
Ovid anticipates its cash runway will support operations and clinical development programs into H1 2026. During this time, Ovid anticipates several events for its current pipeline programs as well as clinical and regulatory results for soticlestat from Takeda.
Tailwinds
- Potential use and development of OV888 (GV101), OV329, OV350 and compounds from Ovid’s library of direct activators of KCC2
- The potential therapeutic opportunity of OV888 (GV101), OV329, OV350 and compounds from Ovid’s library of direct activators of KCC2
- The timing of data readout of topline safety data from Ovid’s Phase 1, double-blind, multiple-ascending dose trial evaluating OV888 (GV101)
- The timing of initiation of Ovid’s Phase 2 clinical program studying OV888 (GV101) in CCM
- Ovid's potential future business development opportunities
Headwinds
- Uncertainties inherent in the preclinical and clinical development and regulatory approval processes
- Risks related to Ovid’s ability to achieve its financial objectives
- The risk that Ovid may not be able to realize the intended benefits of its technology or its business strategy
- Risks related to Ovid’s ability to identify business development targets or strategic partners
- Risks to enter into strategic transactions on favorable terms, or to consummate and realize the benefits of any business development transactions
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2024
-0.5%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+3.6%
Avg return
30 days after
43%
15 / 35 earnings
Positive
+19.5%
Q2 2024
Best reaction
-26.9%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.9% | -5.7% | — | |
| Q4 2025 | +14.4% | +26.9% | +44.8% | |
| Q3 2025 | -2.2% | -3.7% | +21.5% | |
| Q1 2025 | -0.7% | -6.2% | -8.2% | |
| Q4 2024 | +0.1% | -11.4% | -48.0% | |
| Q2 2024 | +19.5% | +33.7% | +31.4% | |
| Q1 2024 | +9.9% | +4.3% | +6.0% | |
| Q4 2023 | -7.3% | -11.0% | +2.5% | |
| Q3 2023 | -7.9% | -4.8% | -9.5% | |
| Q2 2023 | -1.8% | -0.6% | +6.6% | |
| Q1 2023 | -5.2% | -2.5% | +0.1% | |
| Q4 2022 | +4.0% | +13.0% | +46.0% | |
| Q3 2022 | +2.1% | +11.1% | +26.4% | |
| Q2 2022 | +0.5% | +2.3% | -1.4% | |
| Q1 2022 | -12.1% | -22.3% | -30.5% | |
| Q4 2021 | -3.4% | +0.3% | +0.3% | |
| Q3 2021 | -2.8% | +0.8% | -9.7% | |
| Q2 2021 | -9.4% | -13.1% | -14.4% | |
| Q1 2021 | +2.3% | +6.9% | +28.4% | |
| Q4 2020 | +4.4% | +9.0% | -6.1% | |
| Q3 2020 | +18.9% | +19.1% | -49.6% | |
| Q2 2020 | -2.4% | +4.3% | -20.4% | |
| Q1 2020 | -0.3% | +10.6% | +43.7% | |
| Q4 2019 | -26.9% | -31.5% | -7.8% | |
| Q3 2019 | -1.5% | -6.5% | +54.2% | |
| Q2 2019 | -2.1% | -5.2% | +11.9% | |
| Q1 2019 | -14.0% | -20.1% | -24.8% | |
| Q4 2018 | -2.0% | +1.0% | -6.1% | |
| Q3 2018 | -8.0% | -7.9% | -39.1% | |
| Q2 2018 | +2.3% | +8.8% | -0.2% | |
| Q1 2018 | +4.8% | -1.9% | -9.5% | |
| Q4 2017 | -13.1% | -11.4% | +35.7% | |
| Q3 2017 | +15.2% | +20.4% | +49.7% | |
| Q2 2017 | -1.6% | +2.8% | +28.0% | |
| Q1 2017 | +5.3% | +0.4% | -29.7% | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro